Exelixis Inc Payments to Acquire Marketable Securities
Exelixis Inc (EXEL) reported Payments to Acquire Marketable Securities of $342.68 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- Exelixis Inc payments to acquire marketable securities for the quarter ending 2026-07-03 was $68.52M, a 32.48% decline year-over-year.
- Exelixis Inc payments to acquire marketable securities for the quarter ending 2026-04-03 was $274.16M, a 46.84% increase year-over-year.
- Exelixis Inc payments to acquire marketable securities for the quarter ending 2026-01-02 was $154.94M, a 49.26% decline year-over-year.
- Exelixis Inc payments to acquire marketable securities for the quarter ending 2025-10-03 was $189.37M, a 49.55% decline year-over-year.
- Exelixis Inc payments to acquire marketable securities for fiscal 2026 was $632.50M, a 31.84% decline from fiscal 2025.
- Exelixis Inc payments to acquire marketable securities for fiscal 2025 was $927.90M, a 2.82% increase from fiscal 2023.
- Exelixis Inc payments to acquire marketable securities for fiscal 2023 was $902.47M, a 37.79% decline from fiscal 2022.
- Exelixis Inc payments to acquire marketable securities for fiscal 2022 was $1.45B.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-07-03 | $68.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $342.68M 10-Q · filed 2026-08-05 | $497.62M derived: sum of 3 quarters · filed 2026-08-05 | $686.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $274.16M 10-Q · filed 2026-05-05 | $429.10M derived: sum of 2 quarters · filed 2026-05-05 | $618.47M derived: sum of 3 quarters · filed 2026-05-05 | $719.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $154.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $344.31M derived: sum of 2 quarters · filed 2026-02-10 | $445.80M derived: sum of 3 quarters · filed 2026-08-05 | $632.50M 10-K · filed 2026-02-10 |
| 2025-10-03 | $189.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $290.86M derived: sum of 2 quarters · filed 2026-08-05 | $477.56M 10-Q · filed 2025-11-04 | $782.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $101.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $288.19M 10-Q · filed 2026-08-05 | $593.57M derived: sum of 3 quarters · filed 2026-08-05 | $968.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $186.70M 10-Q · filed 2026-05-05 | $492.08M derived: sum of 2 quarters · filed 2026-05-05 | $867.45M derived: sum of 3 quarters · filed 2026-05-05 | $976.14M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $305.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $680.75M derived: sum of 2 quarters · filed 2026-02-10 | $789.44M derived: sum of 3 quarters · filed 2026-02-10 | $927.90M 10-K · filed 2026-02-10 |
| 2024-09-27 | $375.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $484.05M derived: sum of 2 quarters · filed 2025-11-04 | $622.52M 10-Q · filed 2025-11-04 | $701.14M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $108.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $247.15M 10-Q · filed 2025-07-28 | $325.77M derived: sum of 3 quarters · filed 2026-02-10 | |
| 2024-03-29 | $138.47M 10-Q · filed 2025-05-13 | $217.09M derived: sum of 2 quarters · filed 2026-02-10 | ||
| 2023-12-29 | $78.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $902.47M 10-K · filed 2026-02-10 | ||
| 2023-09-29 | $823.85M 10-Q · filed 2024-10-29 | |||
| 2022-12-30 | $1.45B 10-K · filed 2025-02-11 | |||
| 2015-06-30 | $32.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $46.22M 10-Q · filed 2015-08-11 | $56.51M derived: sum of 3 quarters · filed 2015-08-11 | $83.47M derived: sum of 4 quarters · filed 2015-08-11 |
| 2015-03-31 | $13.28M 10-Q · filed 2015-04-30 | $23.57M derived: sum of 2 quarters · filed 2015-04-30 | $50.53M derived: sum of 3 quarters · filed 2015-04-30 | $96.87M derived: sum of 4 quarters · filed 2015-08-11 |
| 2014-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $37.25M derived: sum of 2 quarters · filed 2015-03-02 | $83.59M derived: sum of 3 quarters · filed 2015-08-11 | $119.53M 10-K · filed 2015-03-02 |
| 2014-09-30 | $26.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $73.30M derived: sum of 2 quarters · filed 2015-08-11 | $109.24M 10-Q · filed 2014-11-04 | $122.44M derived: sum of 4 quarters · filed 2015-08-11 |
| 2014-06-30 | $46.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $82.28M 10-Q · filed 2015-08-11 | $95.49M derived: sum of 3 quarters · filed 2015-08-11 | $124.50M derived: sum of 4 quarters · filed 2015-08-11 |
| 2014-03-31 | $35.94M 10-Q · filed 2015-04-30 | $49.14M derived: sum of 2 quarters · filed 2015-04-30 | $78.16M derived: sum of 3 quarters · filed 2015-04-30 | $129.75M derived: sum of 4 quarters · filed 2015-04-30 |
| 2013-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $42.22M derived: sum of 2 quarters · filed 2015-03-02 | $93.82M derived: sum of 3 quarters · filed 2015-03-02 | $189.97M 10-K · filed 2015-03-02 |
| 2013-09-30 | $29.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $80.61M derived: sum of 2 quarters · filed 2014-11-04 | $176.77M 10-Q · filed 2014-11-04 | $350.72M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $51.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $147.75M 10-Q · filed 2014-07-31 | $321.70M derived: sum of 3 quarters · filed 2015-03-02 | $521.00M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $96.16M 10-Q · filed 2014-05-01 | $270.11M derived: sum of 2 quarters · filed 2015-03-02 | $469.41M derived: sum of 3 quarters · filed 2015-03-02 | $516.26M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $173.95M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $373.25M derived: sum of 2 quarters · filed 2015-03-02 | $420.11M derived: sum of 3 quarters · filed 2015-03-02 | $533.48M 10-K · filed 2015-03-02 |
| 2012-09-30 | $199.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $246.16M derived: sum of 2 quarters · filed 2013-10-30 | $359.52M 10-Q · filed 2013-10-30 | $386.16M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $46.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $160.22M 10-Q · filed 2013-08-06 | $186.85M derived: sum of 3 quarters · filed 2014-02-20 | $208.00M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $113.37M 10-Q · filed 2013-05-07 | $140.00M derived: sum of 2 quarters · filed 2014-02-20 | $161.15M derived: sum of 3 quarters · filed 2014-02-20 | $290.57M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $26.63M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $47.78M derived: sum of 2 quarters · filed 2014-02-20 | $177.20M derived: sum of 3 quarters · filed 2014-02-20 | $237.21M 10-K · filed 2014-02-20 |
| 2011-09-30 | $21.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $150.56M derived: sum of 2 quarters · filed 2012-11-07 | $210.58M 10-Q · filed 2012-11-07 | $236.71M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $129.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $189.44M 10-Q · filed 2012-08-02 | $215.57M derived: sum of 3 quarters · filed 2013-02-21 | $253.19M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $60.02M 10-Q · filed 2012-05-03 | $86.15M derived: sum of 2 quarters · filed 2013-02-21 | $123.77M derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $63.75M derived: sum of 2 quarters · filed 2013-02-21 | $167.32M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $37.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $141.19M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $103.56M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $161.17M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |